首页> 美国卫生研究院文献>Journal of Clinical Medicine >The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
【2h】

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines

机译:新型合成无血清培养基OptiPASS可促进MDA-MB-231和SUM1315三阴性乳腺癌细胞系中球体的高增殖和药物功效预测。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Triple-negative breast cancers are particularly aggressive. In vitro cultures are one of the major pathways for developing anticancer strategies. The effectiveness and reproducibility of the drug screenings depend largely on the homogeneity of culture media. In order to optimize the predictive responses of triple-negative breast cancer 3D cell culture models, these works were focused on the development of SUM1315 and MDA-MB-231 cell lines in OptiPASS medium, a new serum-free formulation (BIOPASS). In monolayer cell culture, OptiPASS medium was more suitable for MDA-MB-231 than SUM1315 cell line but maintained cell phenotype and allowed sufficient proliferation. For spheroids produced in OptiPASS, the size monitoring showed a 1.3 and 1.5-fold increase for MDA-MB-231 and SUM1315 cell lines, respectively and viability/mortality profiles were maintained. Spheroids drug sensitivity thresholds were also improved allowing quicker high throughput drug screenings. These results showed the suitability of OptiPASS for 2D and 3D cell cultures of these two triple-negative breast cancer cell lines, with reproducibility of spheroid formation superior to 98%. This opens the way to the common use of this synthetic medium in future preclinical breast cancer research studies.
机译:三阴性乳腺癌尤其具有侵略性。体外培养是开发抗癌策略的主要途径之一。药物筛选的有效性和可重复性在很大程度上取决于培养基的均质性。为了优化三阴性乳腺癌3D细胞培养模型的预测反应,这些工作集中于在OptiPASS培养基(一种新的无血清制剂(BIOPASS))中开发SUM1315和MDA-MB-231细胞系。在单层细胞培养中,与SUM1315细胞系相比,OptiPASS培养基更适合MDA-MB-231,但保持细胞表型并允许足够的增殖。对于在OptiPASS中生产的球体,尺寸监测显示MDA-MB-231和SUM1315细胞系分别增加了1.3倍和1.5倍,并且维持了生存力/死亡率。球形药物敏感性阈值也得到了改善,从而可以更快地进行高通量药物筛选。这些结果表明,OptiPASS适用于这两种三阴性乳腺癌细胞系的2D和3D细胞培养,球体形成的再现性优于98%。这为这种合成培养基在未来的临床前乳腺癌研究中的普遍使用开辟了道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号